CN113855708B - 一种具有抑菌和抗肿瘤活性的海洋长颈虫提取物浸膏 - Google Patents
一种具有抑菌和抗肿瘤活性的海洋长颈虫提取物浸膏 Download PDFInfo
- Publication number
- CN113855708B CN113855708B CN202111263559.XA CN202111263559A CN113855708B CN 113855708 B CN113855708 B CN 113855708B CN 202111263559 A CN202111263559 A CN 202111263559A CN 113855708 B CN113855708 B CN 113855708B
- Authority
- CN
- China
- Prior art keywords
- worm
- long
- necked
- extract
- marine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 50
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 21
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 10
- 241000209140 Triticum Species 0.000 claims abstract description 5
- 235000021307 Triticum Nutrition 0.000 claims abstract description 5
- 235000013339 cereals Nutrition 0.000 claims abstract description 5
- 239000013535 sea water Substances 0.000 claims abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 241000607598 Vibrio Species 0.000 claims description 12
- 238000005119 centrifugation Methods 0.000 claims description 11
- 241000607265 Vibrio vulnificus Species 0.000 claims description 9
- 239000013049 sediment Substances 0.000 claims description 9
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 8
- 241000191967 Staphylococcus aureus Species 0.000 claims description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 229960003085 meticillin Drugs 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 241000700141 Rotifera Species 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 238000009630 liquid culture Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 abstract description 10
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 9
- 230000007613 environmental effect Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 16
- 244000052616 bacterial pathogen Species 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 238000011161 development Methods 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 241000607323 Vibrio campbellii Species 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 241001407024 Vibrio rotiferianus Species 0.000 description 3
- 238000003113 dilution method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241001235566 Dileptus sp. Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 241000242757 Anthozoa Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 241000248487 Moneuplotes crassus Species 0.000 description 1
- 241000243142 Porifera Species 0.000 description 1
- 241000957276 Thalassiosira weissflogii Species 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 241000251555 Tunicata Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229930183674 euplotin Natural products 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/655—Aquatic animals other than those covered by groups A61K35/57 - A61K35/65
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oceanography (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有抑菌和抗肿瘤活性的海洋长颈虫提取物浸膏,涉及原生动物提取物技术领域。本发明包括海洋长颈虫浸膏的制备方法,海洋长颈虫浸膏的制备方法包括从环境中分离纯化长颈虫种群、长颈虫的扩大培养和浸膏制备,从环境中分离纯化长颈虫种群的步骤为:步骤一:从海水中采集原生动物群落,然后在显微镜下吸取一只长颈虫(Dileptussp.);步骤二:然后实验室内用麦粒培养液扩大培养,获得长颈虫的单一种群。本发明的海洋长颈虫浸膏具有较高抑菌和抗肿瘤活性,能用于制备抑菌剂和抗肿瘤药物,并且来源自海洋原生动物,可通过扩大培养持续获得原料,具有环境友好性,应用成本低。
Description
技术领域
本发明属于原生动物提取物技术领域,特别是涉及一种具有抑菌和抗肿瘤活性的海洋长颈虫提取物浸膏。
背景技术
病原微生物感染和恶性肿瘤是人类生命的两大潜在杀手。传统抗生素和抗肿瘤药物的使用使得病原菌和肿瘤产生耐药性。从天然资源中筛选具有抑菌和抗肿瘤活性的次级代谢产物已成为寻找新型、高效、低毒的抑菌和抗肿瘤药物的趋势。
海洋环境中有丰富的生物资源生成活性天然物,可以用来治疗人类疾病。在极端环境下生活的海洋生物,需适应与陆域生物不同的生态压力,包括空间和捕食的竞争,以及诸如盐度、压力和温度变化等物理特性,导致海洋微生物在这一高要求的生态系统中发展了独特的代谢系统和机体防御机制来适应这种环境,从而产生具有种类多样性且复杂高的独特天然化学物质。迄今为止,已从海洋当中的真菌、细菌与微藻等海洋微生物,以及从大型藻类、海绵、珊瑚、软件动物和被囊动物等海洋大型生物中分离出超过36,000种化合物,每年皆发现数百个新颖海洋天然化合物的速度成长。以海洋天然物为基础的新型抗生素和抗肿瘤药物已开始在治疗各类疾病中的临床实验中。
原生生物是无细胞壁真核单细胞动物,虽然结构简单,但具有维持生命和延续后代所必需的一切功能,目前相关领域的研究集中在形态分类学、系统学、细胞发生学、病害学和生态学等几个方面。近年来研究者们在某些海洋原生动物中提取到了一些抗肿瘤活性物质,例如腹毛目的厚游仆虫 (Euplotes crassus) 能产生一种名为 Euplotin 的独特萜类化合物,对利什曼虫有拮抗效应,药学上可作为抗原虫化疗药物的增效物。硅藻Thalassiosira weissflogii中获得SulfavantA衍生物能够提高抗原专一性免疫保护并且延缓黑色素瘤的发生和发展。原生动物抑菌和抗肿瘤活性成分的研究具有重要意义,因此我们提出了一种具有抑菌和抗肿瘤活性的海洋长颈虫提取物浸膏。
发明内容
本发明的目的在于提供一种具有抑菌和抗肿瘤活性的海洋长颈虫提取物浸膏,为寻找高效低毒的抗生素和抗癌药物,突破传统抗生素和抗肿瘤药物的使用中产生耐药性问题提供了资源。
为解决上述技术问题,本发明是通过以下技术方案实现的:
本发明为一种具有抑菌和抗肿瘤活性的海洋长颈虫提取物浸膏,包括海洋长颈虫浸膏的制备方法,所述海洋长颈虫浸膏的制备方法包括从环境中分离纯化长颈虫种群、长颈虫的扩大培养和浸膏制备,所述从环境中分离纯化长颈虫种群的步骤为:
步骤一:从海水中采集原生动物群落,然后在显微镜下吸取一只长颈虫(Dileptussp.);
步骤二:然后实验室内用麦粒培养液扩大培养,获得长颈虫的单一种群。
进一步地,所述长颈虫的扩大培养包括以下步骤:
步骤一:接种长颈虫的单一种群入液体培养基,25℃低速摇床培养2个月;
步骤二:扩大培养达到5L规模,所得的样品进行离心,收集虫体,离心时的转速为3000转/分,离心时间为10分钟。
进一步地,所述浸膏制备包括以下步骤:
步骤一:用甲醇进行萃取,反复萃取3次,萃取的方法是将甲醇加入离心后去除水样的沉积物中,采用高速弥散机将沉积物打成匀浆,离心时的转速为12000转/分,离心时间为10分钟;
步骤二:然后取上清甲醇样,采用旋转蒸发仪浓缩成浸膏,然后用甲醇复溶至5mL,4℃保存备用。
进一步地,所述微生物为耐甲氧西林金黄色葡萄球、轮虫弧菌、坎氏弧菌和创伤弧菌。
进一步地,所述肿瘤为人宫颈癌、人肺癌和人肝癌。
本发明具有以下有益效果:
1、本发明的海洋长颈虫浸膏具有较高抑菌和抗肿瘤活性,能用于制备抑菌剂和抗肿瘤药物,并且来源自海洋原生动物,可通过扩大培养持续获得原料,具有环境友好性,应用成本低。
2、本发明中浸膏对三种肿瘤细胞(宫颈癌Hela细胞、人非小细胞肺癌A549细胞和肝癌HepG2细胞)和五种病原菌(两株耐甲氧西林金黄色葡萄球菌ATCC 43300和CGMCC1.12409、轮虫弧菌Vibrio rotiferianus MCCC 1A08742、坎氏弧菌V. campbellii MCCC1A08741创伤弧菌V. vulnificus MCCC 1A08743)具有较强的抑制作用,表现出较强的广谱体外抑菌、抗肿瘤活性特点,可以用于开发治疗肿瘤药物和抑菌剂,应用前景十分广阔。
当然,实施本发明的任一产品并不一定需要同时达到以上所述的所有优点。
附图说明
为了更清楚地说明本发明实施例的技术方案,下面将对实施例描述所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为本发明的整体连接框图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其它实施例,都属于本发明保护的范围。
请参阅图1所示,本发明为一种具有抑菌和抗肿瘤活性的海洋长颈虫提取物浸膏,包括海洋长颈虫浸膏的制备方法,海洋长颈虫浸膏的制备方法包括从环境中分离纯化长颈虫种群、长颈虫的扩大培养和浸膏制备,从环境中分离纯化长颈虫种群的步骤为:
步骤一:从海水中采集原生动物群落,然后在显微镜下吸取一只长颈虫(Dileptus sp.);
步骤二:然后实验室内用麦粒培养液扩大培养,获得长颈虫的单一种群。
长颈虫的扩大培养包括以下步骤:
步骤一:接种长颈虫的单一种群入液体培养基,25℃低速摇床培养2个月;
步骤二:扩大培养达到5L规模,所得的样品进行离心,收集虫体,离心时的转速为3000转/分,离心时间为10分钟。
浸膏制备包括以下步骤:
步骤一:用甲醇进行萃取,反复萃取3次,萃取的方法是将甲醇加入离心后去除水样的沉积物中,采用高速弥散机将沉积物打成匀浆,离心时的转速为12000转/分,离心时间为10分钟,其中高速弥散机的产品编号:T25 DS25。
步骤二:然后取上清甲醇样,采用旋转蒸发仪浓缩成浸膏,然后用甲醇复溶至5mL,4℃保存备用,旋转蒸发仪的产品编号:Hei-VAP value。
微生物为耐甲氧西林金黄色葡萄球、轮虫弧菌、坎氏弧菌和创伤弧菌,肿瘤为人宫颈癌、人肺癌和人肝癌,本发明中海洋长颈虫浸膏具有较高抑菌和抗肿瘤活性,能用于制备抑菌剂和抗肿瘤药物,并且来源自海洋原生动物,可通过扩大培养持续获得原料,具有环境友好性,应用成本低,使用范围较广泛,同时浸膏对三种肿瘤细胞(宫颈癌Hela细胞、人非小细胞肺癌A549细胞和肝癌HepG2细胞)和五种病原菌(两株耐甲氧西林金黄色葡萄球菌ATCC43300和CGMCC 1.12409、轮虫弧菌V. rotiferianus MCCC 1A08742、坎氏弧菌V. campbellii MCCC 1A08741创伤弧菌V. vulnificus MCCC 1A08743)有较强的抑制作用,表现出较强的广谱体外抑菌、抗肿瘤活性特点,同时可以用于耐甲氧西林金黄色葡萄球菌、轮虫弧菌、坎氏弧菌和创伤弧菌抑菌剂及治疗宫颈癌细胞、肺癌细胞和肝癌细胞的药物开发,应用前景十分广阔。
实施例一:微量稀释法测定海洋长颈虫浸膏抑菌活性
1.本实施例采用微量稀释法,检测培养病原微生物中加入海洋长颈虫浸膏的菌体浓度抑制情况,来测定海洋长颈虫浸膏的抑菌活性。
2.两株耐甲氧西林金黄色葡萄球菌MRSA ATCC 43300和CGMCC 1.12409、轮虫弧菌V. rotiferianus MCCC 1A08742、坎氏弧菌V. campbellii MCCC 1A08741创伤弧菌V. vulnificus MCCC 1A08743,采用OD600测定每种菌抑制率90%时的最低抑菌浓度MIC(以上菌株可以购自ATCC、CGMCC和MCCC)。
海洋长颈虫浸膏对上述病原菌的最低抑菌浓度MIC如表1 所示
表1. 海洋长颈虫浸膏的最低抑菌浓度MIC结果表
实施例验证了本发明的海洋长颈虫浸膏能有效抑制多种病原细菌的增殖,具体包括耐甲氧西林金黄色葡萄球菌ATCC 43300和CGMCC 1.12409、轮虫弧菌V. rotiferianusMCCC 1A08742、坎氏弧菌V. campbellii MCCC 1A08741创伤弧菌V. vulnificus MCCC1A08743。采用微量稀释法测定病原菌抑制率为90%时的最低抑菌浓度MIC,结果如表1所示,最低抑菌浓度MIC均在15.27~18.72μg/mL 之间。本发明的海洋长颈虫浸膏有效地抑制了上述病原细菌的增殖,其抑制病原菌增殖的活性较高,能用于制备抑菌剂,开发和应用前景十分广阔。
实施例二:MTT法测定海洋长颈虫浸膏抗肿瘤活性
1.本实施例采用体外细胞毒实验,检测离体培养的的人肿瘤细胞中加入海洋长颈虫浸膏后的存活率,来测定海洋长颈虫浸膏的抗肿瘤活性。
2.选取的细胞株有:人宫颈癌Hela细胞、人非小细胞肺癌A549细胞和人肝癌HepG2细胞。采用MTT法来测定定每种肿瘤细胞的存活率 (或死亡率) 为50%时的半抑制浓度IC50(以上细胞均可以购自ATCC),海洋长颈虫浸膏对上述肿瘤细胞的半抑制浓度IC50如表2 所示。
表2. 海洋长颈虫浸膏的的抗肿瘤细胞半抑制浓度IC50结果表
实施例验证了本发明的海洋长颈虫浸膏能有效抑制多种肿瘤细胞的增殖,具体包括宫颈癌Hela细胞、人非小细胞肺癌A549细胞和肝癌HepG2细胞。采用MTT 法来测定每种肿瘤细胞的存活率(或死亡率)为50%时的半抑制浓度IC50,结果如表2所示,半抑制浓度均在4.67~10.87 μg/mL之间。本发明的海洋长颈虫浸膏有效地抑制了上述肿瘤细胞的增殖,其抑制细胞增殖的活性较高,能用于制备抗肿瘤药物,开发和应用前景十分广阔。
本实施例的一个具体应用为:首先从海水中采集原生动物群落,然后在显微镜下吸取一只长颈虫(Dileptus sp.),然后在实验室内用麦粒培养液扩大培养,获得长颈虫的单一种群,接种长颈虫的单一种群入液体培养基,25℃低速摇床培养2个月,并扩大培养达到5L规模,所得的样品进行离心,收集虫体,离心时的转速为3000转/分,离心时间为10分钟,然后用甲醇进行萃取,反复萃取3次,萃取的方法是将甲醇加入离心后去除水样的沉积物中,采用高速弥散机将沉积物打成匀浆,离心时的转速为12000转/分,离心时间为10分钟,并取上清甲醇样,采用旋转蒸发仪浓缩成浸膏,然后用甲醇复溶至5mL,4℃保存备用,完成浸膏的制备,使海洋长颈虫浸膏具有较高抑菌和抗肿瘤活性,能用于制备抑菌剂和抗肿瘤药物,并且来源自海洋原生动物,可通过扩大培养持续获得原料,具有环境友好性,应用成本低,可以被全面推广使用。
在本说明书的描述中,参考术语“一个实施例”、“示例”、“具体示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中,对上述术语的示意性表述不一定指的是相同的实施例或示例。而且,描述的具体特征、结构、材料或者特点可以在任何的一个或多个实施例或示例中以合适的方式结合。
以上公开的本发明优选实施例只是用于帮助阐述本发明。优选实施例并没有详尽叙述所有的细节,也不限制该发明仅为所述的具体实施方式。显然,根据本说明书的内容,可作很多的修改和变化。本说明书选取并具体描述这些实施例,是为了更好地解释本发明的原理和实际应用,从而使所属技术领域技术人员能很好地理解和利用本发明。本发明仅受权利要求书及其全部范围和等效物的限制。
Claims (1)
1.一种具有抑菌和抗肿瘤活性的海洋长颈虫提取物浸膏,包括海洋长颈虫浸膏的制备方法,其特征在于:所述海洋长颈虫浸膏的制备方法包括从环境中分离纯化长颈虫种群、长颈虫的扩大培养和浸膏制备,所述从环境中分离纯化长颈虫种群的步骤为:
步骤一:从海水中采集原生动物群落,然后在显微镜下吸取一只长颈虫(Dileptussp.);
步骤二:然后实验室内用麦粒培养液扩大培养,获得长颈虫的单一种群;
所述长颈虫的扩大培养包括以下步骤:
步骤一:接种长颈虫的单一种群入液体培养基,25℃低速摇床培养2个月;
步骤二:扩大培养达到5L规模,所得的样品进行离心,收集虫体,离心时的转速为3000转/分,离心时间为10分钟;
所述浸膏制备包括以下步骤:
步骤一:用甲醇进行萃取,反复萃取3次,萃取的方法是将甲醇加入离心后去除水样的沉积物中,采用高速弥散机将沉积物打成匀浆,离心时的转速为12000转/分,离心时间为10分钟;
步骤二:然后取上清甲醇样,采用旋转蒸发仪浓缩成浸膏,然后用甲醇复溶至5mL,4℃保存备用;
所述抑菌为抑制耐甲氧西林金黄色葡萄球菌、轮虫弧菌、坎氏弧菌和创伤弧菌;
所述肿瘤为人宫颈癌、人肺癌和人肝癌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111263559.XA CN113855708B (zh) | 2021-10-28 | 2021-10-28 | 一种具有抑菌和抗肿瘤活性的海洋长颈虫提取物浸膏 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111263559.XA CN113855708B (zh) | 2021-10-28 | 2021-10-28 | 一种具有抑菌和抗肿瘤活性的海洋长颈虫提取物浸膏 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113855708A CN113855708A (zh) | 2021-12-31 |
CN113855708B true CN113855708B (zh) | 2024-04-19 |
Family
ID=78998258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111263559.XA Active CN113855708B (zh) | 2021-10-28 | 2021-10-28 | 一种具有抑菌和抗肿瘤活性的海洋长颈虫提取物浸膏 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113855708B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101586148A (zh) * | 2009-06-26 | 2009-11-25 | 河北大学 | 一种应用原生动物纤毛虫降解石油的方法 |
KR20100054675A (ko) * | 2008-11-14 | 2010-05-25 | 부경대학교 산학협력단 | 해양 동물 플랑크톤 배양액 중의 대사산물을 유효성분으로 하는 간 기능 개선용 조성물 및 그 제조 방법 |
CN103122318A (zh) * | 2012-12-25 | 2013-05-29 | 浙江工业大学 | 一株海洋真菌桔青霉及其在制备抗肿瘤药物中的应用 |
CN112300156A (zh) * | 2020-10-15 | 2021-02-02 | 滨州医学院附属医院 | 一种海洋来源的抗肿瘤活性化合物及其制备方法、应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ300806B6 (cs) * | 2007-07-18 | 2009-08-12 | Ústav experimentální mediciny AV CR, v.v.i. | Imunostimulacní úcinky trilobolidu a zpusob jeho prípravy |
-
2021
- 2021-10-28 CN CN202111263559.XA patent/CN113855708B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100054675A (ko) * | 2008-11-14 | 2010-05-25 | 부경대학교 산학협력단 | 해양 동물 플랑크톤 배양액 중의 대사산물을 유효성분으로 하는 간 기능 개선용 조성물 및 그 제조 방법 |
CN101586148A (zh) * | 2009-06-26 | 2009-11-25 | 河北大学 | 一种应用原生动物纤毛虫降解石油的方法 |
CN103122318A (zh) * | 2012-12-25 | 2013-05-29 | 浙江工业大学 | 一株海洋真菌桔青霉及其在制备抗肿瘤药物中的应用 |
CN112300156A (zh) * | 2020-10-15 | 2021-02-02 | 滨州医学院附属医院 | 一种海洋来源的抗肿瘤活性化合物及其制备方法、应用 |
Non-Patent Citations (1)
Title |
---|
张文.海洋药物导论 第2版.上海科学技术出版社,2012,第60页. * |
Also Published As
Publication number | Publication date |
---|---|
CN113855708A (zh) | 2021-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Najdenski et al. | Antibacterial and antifungal activities of selected microalgae and cyanobacteria | |
Lampert et al. | Chemical induction of colony formation in a green alga (Scenedesmus acutus) by grazers (Daphnia) | |
Ibrahim et al. | Callyspongia crassa and C. siphonella (Porifera, Callyspongiidae) as a potential source for medical bioactive substances, Aqaba Gulf, Red Sea, Egypt | |
Samuel et al. | Antibacterial activity of marine derived fungi collected from South East Coast of Tamilnadu, India | |
Onishi et al. | The seagrass Zostera marina harbors growth-inhibiting bacteria against the toxic dinoflagellate Alexandrium tamarense | |
Amer et al. | Chitosan from marine-derived Penicillum spinulosum MH2 cell wall with special emphasis on its antimicrobial and antifouling properties | |
CN107974427B (zh) | 一株具有抑菌活性的海洋链霉菌 | |
CN106434783A (zh) | 一种苯并吡喃酮化合物及其制备方法和在制备抗菌药物中的应用 | |
Afroz et al. | Saccharomyces cerevisiae as an untapped source of fungal chitosan for antimicrobial action | |
Mokhtari-Hosseini et al. | Chitin and chitosan biopolymer production from the Iranian medicinal fungus Ganoderma lucidum: Optimization and characterization | |
Senousy et al. | Biochemical analyses of ten cyanobacterial and microalgal strains isolated from egyptian habitats, and screening for their potential against some selected phytopathogenic fungal strains | |
Kavisri et al. | Phytochemistry, bioactive potential and chemical characterization of metabolites from marine microalgae (Spirulina platensis) biomass | |
Hassan et al. | Optimization of antibacterial compounds production by Aspergillus fumigatus isolated from Sudanese indigenous soil | |
Nongkhlaw et al. | Micrographical assessment of antifungal effect of endophytic bacteria | |
CN113855708B (zh) | 一种具有抑菌和抗肿瘤活性的海洋长颈虫提取物浸膏 | |
Yegorenkova et al. | Immunomodulatory activity of exopolysaccharide from the rhizobacterium Paenibacillus polymyxa CCM 1465 | |
Venkatesan et al. | First report of Clonostachys rosea as a Mycoparasite on Sclerotinia sclerotiorum causing head rot of cabbage in India | |
Unpaprom et al. | Antibacterial, antifungal properties and chemical composition of freshwater macroalage, Cladophora glomerata | |
Lubobi et al. | Isolation of bioactive secondary metabolites from seaweeds Amphiroa anceps against chicken meat associated pathogens | |
CN102102082A (zh) | 海带内生活性菌株的分离纯化方法 | |
Devi et al. | Screening of suitable culture media for growth, cultural and morphological characters of Pycnidia forming fungi | |
CN109400444B (zh) | 抑制植物病源真菌的倍半萜类化合物及其制备方法 | |
Rossiana et al. | Antibacterial activities of endophytic fungi from mangrove plants Rhizophora apiculata L. and Bruguiera gymnorrhiza (L.) Lamk. on Salmonella typhi | |
Elkomy et al. | Antimicrobial activity of three microalgae isolated from Mediterranean Sea coast, Egypt | |
CN100411520C (zh) | 一种抗灰霉病的生物杀菌剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |